Journal ArticleOPEN ACCESS

Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies

  • Migden M
  • Paccaly A
  • Papadopoulos K
  • et al.
Annals of Oncology (2019) 30 v520
DOI: 10.1093/annonc/mdz253.104
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cemiplimab (cemiplimab-rwlc in the US), a human monoclonal anti–PD-1 antibody, has shown substantial antitumour activity in pts with advanced malignancies and is FDA-approved for pts with advanced (metastatic or locally advanced) cutaneous squamous cell carcinoma (CSCC). We sought to compare weight-based and fixed dosing regimens of cemiplimab in pts with advanced malignancies.

Cite

CITATION STYLE

APA

Migden, M. R., Paccaly, A., Papadopoulos, K. P., Yang, F., Davis, J. D., Rippley, R., … Rischin, D. (2019). Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies. Annals of Oncology, 30, v520. https://doi.org/10.1093/annonc/mdz253.104

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free